Subcutaneous methotrexate injection in the treatment of rheumatoid arthritis;Podskórne iniekcje metotreksatu w leczeniu reumatoidalnego zapalenia stawów

Reumatologia

Volumn 45, Issue 6, 2007, Pages 407-414

  Świerkot, Jerzy ^a,b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b NONE   (Poland)

Author keywords

Methotrexate; Rheumatoid arthritis

Indexed keywords

EID: 38549099664     PISSN: 00346233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Segal R, Yaron M, Tartakovsky B. Methotrexate: Mechanism of action in rheumatoid arthritis. Semin Arthritis Rheum 1990; 20: 190-199.
2. Cronstein BN. The mechanism of action of Methotrexate. Rheum Dis Clin N Am 1997; 23: 739-755
3. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 1990; 33: 1449-1461.
4. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum 1992; 35: 1117-1125.
5. Furst DE. Rational use of disease-modifying antirheumatic drugs. Drugs 1990; 39: 19-37.
6. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159: 2542-2550.
7. Aletaha D, Stamm T, Kapral T, et al. Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis 2003; 62: 944-951.
8. Świerkot J, Szechiński J, Wiland P. Piȩcioletnia ocena kliniczna skuteczności leczenia metotreksatem chorych na reumatoidalne zapalenie stawów. Pol Arch Med Wewn 2000; 103: 5-6, 267-275.
9. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: second line drugs and prednisone. J Rheumatol 1992; 19: 1885-1894.
10. Schiff M, Keystone E, Cush J, et al. Discontinuation of DMARD therapy in patients with rheumatoid arthritis enrolled in RADIUS 1-rates, reason, and predictors of early drug withdrawal. RA-TreatmentII. Program and abstracts of the American College of Rheumatology 67th Annual Scientific Meeting; October 23-28, Orlando, Florida Abstract S1708.
11. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46: 1443-1450.
12. Paulus HE. Protocol development for combination therapy with disease-modifying antirheumatic drugs. Semin Arthritis Rheum 1993; 23 (suppl 1): 19-25
13. Bingham SJ, Buch MH, Lindsay S, et al. Parenteral methotrexate should be given before biological therapy. Rheumatology (Oxford) 2003; 42: 1009-1010.
14. Creinin MD, Krohn MA. Methotrexate pharmacokinetics and effects in women receiving methotrexate 50 mg and 60 mg per square meter for early abortion. Am J Obstet Gynecol 1997; 177: 1444-1449.
15. Jundt JW, Browne BA, Fiocco GP, et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993; 20: 1845-1849.
16. Kabisch S, Weigand T, Plischke H, Menninger H. Bioavailability of methotrexate (MTX) following different routes of application. Akt Rheumatol 2004; 29: 197-200.
17. Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 2004; 31: 645-648.
18. Robbins L, et al. Methotrexate use in rheumatic diseases: comperison of efficacy and tolerance of oral, intramuscular and subcutaneous methods of administration. Arthritis Rheum 1997; 40: 230.
19. Braun J, Kaestner P, Flaxenberg P, et al. The clinical efficacy and safety of subcutaneous (s.c.) versus oral application of methotrexate (MTX) in patients with active rheumatoid arthritis (RA) - results of a randomized, controlled, double-blind, multi-center study. Ann Rheum Dis 2006; 65 (supl II): 87.
20. Brandt A. Results of an observational study with parenteral MTX. Medac GmbH Germany 2004.
21. Alsufyani K, Ortiz-Alvarez O, Cabral DA, et al. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who failed oral methotrexate. J Rheumatol 2004; 31: 179-182.
22. Ramanan AV, Whitworth P, Baildam EM. Use of methotrexate in juvenile idiopathic arthritis. Arch Dis Child 2003; 88: 197-200.
23. Hoekstra M, van Ede AE, Haagsma CJ, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62: 423-426.
24. Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum 2004; 50: 1370-1382.
25. KimYI. 5,10-Methylenetetrahydrofolate reductase polymorphisms and pharmacogenetics: a new role of single nucleotide polymorphisms in the folate metabolic pathway in human health and disease. Nutr Rev 2005; 63: 398-407.
26. Chizyński K. Hiperhomocysteinemia - ważny czynnik ryzyka choroby niedokrwiennej serca. Pol Przegl Kardiol 2002; 4: 103-108.
27. Berkun Y, Levartovsky D, Rubinow A, et al. Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis 2004; 63: 1227-1231.
28. van Ede AE, Laan RF, Blom HJ, et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 2001; 44: 2525-2530.
29. Choi HK, Hernán MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-1177.
30. Singer RB.Mortality in rheumatoid arthritis patients treated with or without methotrexate. J Insur Med 2003; 35: 144-149.
31. Prodanowich S, Ma F, Taylor JR, et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005; 52: 262-267.
32. Krause D, Schleusser B, Herborn G, et al. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000; 43: 14-21.